Is it possible to increase stability of apheresis/leukapheresis cell products?

Published: 11 March 2019

    With the increased development and regulatory/marketing approvals of cell immunotherapies, there has been greater recognition of the starting material variability, and potential cell product manufacturing impact vulnerability from the starting material quality. The clinical and industry interest on the topic of apheresis/leukapheresis material quality has generated discussions in various circles regarding gaps in […]

Read now